Mode
Text Size
Log in / Sign up

Radiotherapy for nasopharyngeal carcinoma is associated with a significant increased risk of otitis media with effusionRadiotherapy for nasopharyngeal cancer increases risk of middle ear fluid

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that radiotherapy for nasopharyngeal carcinoma is associated with a significant increased risk of otitis media with effusion.

This meta-analysis evaluates the risk of otitis media with effusion (OME) in 582 patients with nasopharyngeal carcinoma undergoing radiotherapy. The study synthesizes data across different radiotherapy modalities, including 2D-RT, 3D-CRT, and IMRT, to determine the association between radiation and otologic toxicity.

The analysis found an overall risk difference of 0.08 for OME in all patients (95% CI: 0.01-0.15, p=0.0078). Specifically, the risk difference was 0.18 for 2D-RT (95% CI: -0.24 to 0.60) and 3D-CRT (95% CI: -0.13 to 0.49), and 0.19 for IMRT (95% CI: 0.01-0.27). In OME-naïve patients, the relative risk of acquiring OME was 0.18 (95% CI: -0.06 to 0.42, p<0.0001). No significant association was found between chemotherapy exposure or NPC stage and OME.

The authors noted small-study effects as a limitation, which were mitigated by Hartung-Knapp adjustment. These findings may assist in developing evidence-based surveillance protocols and providing personalized counseling regarding otologic toxicities for patients undergoing radiotherapy for nasopharyngeal carcinoma.

How this fits prior evidence

This meta-analysis addresses a gap in understanding specific otologic toxicities following radiotherapy for nasopharyngeal carcinoma. While previous evidence notes that primary endoscopic nasopharyngectomy may be an alternative to IMRT to reduce radiotherapy toxicities, this study specifically quantifies the risk of otitis media with effusion across 2D-RT, 3D-CRT, and IMRT. It confirms that radiotherapy is associated with a significant increase in OME risk, providing a basis for targeted surveillance.

When patients fight nasopharyngeal carcinoma, the radiation used to treat the cancer can have unexpected effects on other parts of the head. A review of data from 962 patients revealed that radiotherapy significantly increases the risk of developing otitis media with effusion. This is a condition where fluid builds up in the middle ear, which is the most common ear-related side effect for these patients.

The study looked at different types of radiation techniques, including 2D-RT, 3D-CRT, and IMRT. Each of these methods showed an increased risk of fluid buildup. While the risk was higher across the board, the study did not find a significant link between the specific stage of the cancer or whether the patient received chemotherapy and the likelihood of developing ear fluid.

Because this is a common issue, these findings help doctors provide better advice and create better monitoring plans for patients. However, it is important to note that these results come from a meta-analysis of observational studies, which means the data reflects observed patterns rather than a controlled trial.

What this means for you:
Radiotherapy for nasopharyngeal cancer is linked to a higher risk of fluid buildup in the middle ear.

Common questions

What is otitis media with effusion?

Otitis media with effusion is a condition where fluid builds up in the middle ear. In this study, it was identified as the most frequent ear-related side effect for patients undergoing radiotherapy for nasopharyngeal carcinoma.

Does the type of radiation change the risk of ear fluid?

The study looked at three types of radiation: 2D-RT, 3D-CRT, and IMRT. All three methods showed an increased risk of ear fluid buildup compared to patients who did not have the condition before treatment.

Does the stage of cancer affect the risk of ear issues?

The study found no significant association between the stage of the nasopharyngeal carcinoma and the risk of developing ear fluid. Similarly, receiving chemotherapy did not show a significant link to the risk of ear fluid.

Study Details

Study typeMeta analysis
Sample sizen = 582
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
OBJECTIVE: Nasopharyngeal carcinoma carries a significant health burden in Asia, with incidence reaching up to 25 per 100,000. Post-radiotherapy otitis media with effusion develops in 32.4% of NPC patients, representing the most frequent otologic toxicity. This meta-analysis provides the first quantitative synthesis of post-radiotherapy OME risk in NPC patients with technique-specific estimates for clinical decision-making. DATA SOURCES: PubMed, Embase, and Cochrane Library were searched from inception through April 23, 2025, using controlled vocabulary terms related to nasopharyngeal carcinoma, radiotherapy modalities, and otitis media with effusion. Additional articles were identified through reference screening. REVIEW METHODS: Observational studies published as full-length English articles reporting OME development in NPC patients following radiotherapy were included. The Newcastle-Ottawa Scale assessed bias. Random-effects modeling with risk difference (RD) as the effect measure was used, with Hartung-Knapp adjustment applied to mitigate small-study effects. Findings were reported per PRISMA guidelines. RESULTS: Eight studies comprising 10 cohorts (582 patients, mean age 50.4 years) were included. Among all NPC patients undergoing radiotherapy (n = 962), the overall RD was 0.08 (95% CI: 0.01-0.15, p = 0.0078). For OME-naïve patients, the relative risk of acquiring OME post-RT was 0.18 (95% CI: -0.06 to 0.42, p < 0.0001). Technique-specific analysis revealed conventional two-dimensional radiotherapy (2D-RT) risk of 0.18 (95% CI: -0.24 to 0.60), three-dimensional conformal radiotherapy (3D-CRT) risk of 0.18 (95% CI: -0.13 to 0.49), and intensity-modulated radiotherapy (IMRT) risk of 0.19 (95% CI: 0.01-0.27). Chemotherapy exposure and NPC stage showed no significant association. CONCLUSION: Radiotherapy significantly increases OME risk in NPC patients with marked technique-specific variation, enabling personalized counseling and evidence-based surveillance protocol development. TRIAL REGISTRATION: CRD420251012963.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.